Clinical Trials
42
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (38 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 212
- Registration Number
- NCT06239311
- Locations
- 🇨🇿
MU Dr. Petr Arenberger, DrSc. MBA, Prague, Praha 1, Czechia
🇨🇿Synexus Czech s.r.o., Prague, Praha 2, Czechia
🇨🇿Praglandia s.r.o., Prague, Praha 5, Czechia
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants with Steroid-Refractory Acute Graft Versus Host Disease
- Conditions
- Steroid-refractory Acute Graft-versus-host Disease
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT06075706
- Locations
- 🇫🇷
CHU de Bordeaux - Hopital des Enfants, Bordeaux, France
🇫🇷CHU Grenoble Alpes - Hopital Couple Enfant (HCE), La Tronche, France
🇫🇷Centre Hospitalier Universitaire de Lille CHU Lille - Hopital Jeanne de Flandre HJF, Lille, France
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
- Conditions
- Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT05534620
- Locations
- 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy
- Conditions
- Steroid-refractory Acute Graft-versus-host Disease
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 210
- Registration Number
- NCT04629833
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU) Amiens-Picardie - Hopital Sud, Amiens, France
🇫🇷CHU Jean Minjoz, Besancon, France
🇫🇷CHU de Nantes - Hotel Dieu, Nantes, France
PK, PD, Safety and Immunogenicity of Spectrila in Adults with Acute B-cell Lymphoblastic Leukaemia
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT03156790
- Locations
- 🇧🇷
Hospital Rio Grande Natal, Rio Grande do Norte, Brazil
🇧🇷Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
🇧🇷Universidade Estadual de Campinas, Campinas, Brazil
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
FDA Approves GRAFAPEX (Treosulfan) for Injection in AlloHSCT Conditioning Regimen
The FDA has approved GRAFAPEX (treosulfan) in combination with fludarabine for allogeneic hematopoietic stem cell transplantation (alloHSCT) conditioning.